Cargando…
A Comprehensive Overview of Targeted Therapy in Metastatic Renal Cell Carcinoma
Chemotherapy and immunotherapy failed to deliver decisive results in the systemic treatment of metastatic renal cell carcinoma. Agents representing the current standards operate on members of the RAS signal transduction pathway. Sunitinib (targeting vascular endothelial growth factor), temsirolimus...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3434473/ https://www.ncbi.nlm.nih.gov/pubmed/22515521 http://dx.doi.org/10.2174/156800912802429265 |
_version_ | 1782242450012635136 |
---|---|
author | Mihály, Z Sztupinszki, Z Surowiak, P Győrffy, B |
author_facet | Mihály, Z Sztupinszki, Z Surowiak, P Győrffy, B |
author_sort | Mihály, Z |
collection | PubMed |
description | Chemotherapy and immunotherapy failed to deliver decisive results in the systemic treatment of metastatic renal cell carcinoma. Agents representing the current standards operate on members of the RAS signal transduction pathway. Sunitinib (targeting vascular endothelial growth factor), temsirolimus (an inhibitor of the mammalian target of rapamycin - mTOR) and pazopanib (a multi-targeted receptor tyrosine kinase inhibitor) are used in the first line of recurrent disease. A combination of bevacizumab (inhibition of angiogenesis) plus interferon α is also first-line therapy. Second line options include everolimus (another mTOR inhibitor) as well as tyrosine kinase inhibitors for patients who previously received cytokine. We review the results of clinical investigations focusing on survival benefit for these agents. Additionally, trials focusing on new agents, including the kinase inhibitors axitinib, tivozanib, dovitinib and cediranib and monoclonal antibodies including velociximab are also discussed. In addition to published outcomes we also include follow-up and interim results of ongoing clinical trials. In summary, we give a comprehensive overview of current advances in the systemic treatment of metastatic renal cell carcinoma. |
format | Online Article Text |
id | pubmed-3434473 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Bentham Science Publishers |
record_format | MEDLINE/PubMed |
spelling | pubmed-34344732012-09-07 A Comprehensive Overview of Targeted Therapy in Metastatic Renal Cell Carcinoma Mihály, Z Sztupinszki, Z Surowiak, P Győrffy, B Curr Cancer Drug Targets Article Chemotherapy and immunotherapy failed to deliver decisive results in the systemic treatment of metastatic renal cell carcinoma. Agents representing the current standards operate on members of the RAS signal transduction pathway. Sunitinib (targeting vascular endothelial growth factor), temsirolimus (an inhibitor of the mammalian target of rapamycin - mTOR) and pazopanib (a multi-targeted receptor tyrosine kinase inhibitor) are used in the first line of recurrent disease. A combination of bevacizumab (inhibition of angiogenesis) plus interferon α is also first-line therapy. Second line options include everolimus (another mTOR inhibitor) as well as tyrosine kinase inhibitors for patients who previously received cytokine. We review the results of clinical investigations focusing on survival benefit for these agents. Additionally, trials focusing on new agents, including the kinase inhibitors axitinib, tivozanib, dovitinib and cediranib and monoclonal antibodies including velociximab are also discussed. In addition to published outcomes we also include follow-up and interim results of ongoing clinical trials. In summary, we give a comprehensive overview of current advances in the systemic treatment of metastatic renal cell carcinoma. Bentham Science Publishers 2012-09 2012-09 /pmc/articles/PMC3434473/ /pubmed/22515521 http://dx.doi.org/10.2174/156800912802429265 Text en © 2012 Bentham Science Publishers http://creativecommons.org/licenses/by/2.5/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.5/), which permits unrestrictive use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Article Mihály, Z Sztupinszki, Z Surowiak, P Győrffy, B A Comprehensive Overview of Targeted Therapy in Metastatic Renal Cell Carcinoma |
title | A Comprehensive Overview of Targeted Therapy in Metastatic Renal Cell Carcinoma |
title_full | A Comprehensive Overview of Targeted Therapy in Metastatic Renal Cell Carcinoma |
title_fullStr | A Comprehensive Overview of Targeted Therapy in Metastatic Renal Cell Carcinoma |
title_full_unstemmed | A Comprehensive Overview of Targeted Therapy in Metastatic Renal Cell Carcinoma |
title_short | A Comprehensive Overview of Targeted Therapy in Metastatic Renal Cell Carcinoma |
title_sort | comprehensive overview of targeted therapy in metastatic renal cell carcinoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3434473/ https://www.ncbi.nlm.nih.gov/pubmed/22515521 http://dx.doi.org/10.2174/156800912802429265 |
work_keys_str_mv | AT mihalyz acomprehensiveoverviewoftargetedtherapyinmetastaticrenalcellcarcinoma AT sztupinszkiz acomprehensiveoverviewoftargetedtherapyinmetastaticrenalcellcarcinoma AT surowiakp acomprehensiveoverviewoftargetedtherapyinmetastaticrenalcellcarcinoma AT gyorffyb acomprehensiveoverviewoftargetedtherapyinmetastaticrenalcellcarcinoma AT mihalyz comprehensiveoverviewoftargetedtherapyinmetastaticrenalcellcarcinoma AT sztupinszkiz comprehensiveoverviewoftargetedtherapyinmetastaticrenalcellcarcinoma AT surowiakp comprehensiveoverviewoftargetedtherapyinmetastaticrenalcellcarcinoma AT gyorffyb comprehensiveoverviewoftargetedtherapyinmetastaticrenalcellcarcinoma |